ZYBERNO
Stock Report
Updated Aug 21, 2026

PRECISION BIOSCIENCES INC (DTIL)

Healthcare • NASDAQ

$8.80

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
21.0/100
POOR BUSINESS
PRECISION BIOSCIENCES INC (DTIL) scores 21/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-168.2%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.25x)
Operating Margin (Operational Efficiency):CRITICAL (-178.4%)
Return on Capital (Capital Efficiency):CRITICAL (-151.3%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

PRECISION BIOSCIENCES INC (DTIL) stock report — Zyberno Score 21/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, DTIL generated -$58.77M in Owner Earnings. Capital was deployed as follows: $39.00K invested in capital expenditures. Reinvestment rate: 2.3%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:8.80
Market Cap:$227.54M

Valuation Multiples (3)

P/B Ratio:5.02x
P/S Ratio:5.05x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$147.14M

Price Action & Momentum (3)

Momentum Percentile:90 / 100
% of 52-Week High:91.5%
B. Profitability Assessment

Return Metrics (5)

ROA:-74.8%
Reinvestment Rate:2.3%
Fundamental Growth Rate (g):-3.5%

Margin Analysis (3)

Operating Margin Ttm:-178.4%
Net Margin Ttm:-214.9%
Ebitda Margin:-175.4%

TTM Performance (2)

Operating Margin Ttm:-178.4%
Net Margin Ttm:-214.9%

Yield Metrics (2)

Earnings Yield:-$76.30
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:18.4%
Latest Earnings Filed:2026-08-06

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-50.0%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:12.82x
Quick Ratio:12.82x
Cash Ratio:12.06x

Leverage Analysis (3)

Debt To Equity Ttm:0.25x
Debt-to-Equity Ratio:0.25x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-39.48x
Times Interest Earned:-39.48

Capital Structure (4)

Working Capital:84,409,000.00
Cash And Cash Equivalents:86,076,000.00
Long Term Debt:$4.07M
Net Debt:-$80.40M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $45.06M
Linear Growth: -50.0%
📊 Click to view full DTIL Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$80.38M

Bottom Line Performance (3)

-$96.82M
Income Before Tax:-$45.72M
Ebitda Ttm:-79,012,000.00

Operating Expenses (5)

Operating Expenses:81,450,000.00
R And D Expense:53,320,000.00
Sga Expense:28,130,000.00
Income Tax Expense:$0.00
Interest Expense:1,321,000.00

Expense Ratios (1)

Ebitda Margin:-175.4%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$125.92M
Current Assets:$91.55M
Ppe Net:964,000.00
Goodwill:0.00
Intangible Assets:$1.09M

Liability Structure (4)

Total Liabilities:80,627,000.00
Current Liabilities:7,140,000.00
Long Term Debt:$4.07M
Short Term Debt:$1.61M

Equity & Capital (3)

Equity:$45.29M
Retained Earnings:-$579.28M
Common Stock:200,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:828,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:1,844,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$58.73M-$58.77M

Investment Activities (2)

Investing Cash Flow:-$114.00K
Capital Expenditures Ttm:39,000.00

Financing Activities (3)

Financing Cash Flow:$745.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:1,372,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-5.57
-$5.57
Earnings Per Share Ttm:-$3.74

Revenue & Cash Per Share (2)

Sales Per Share Ttm:1.74
Operating Cash Flow Per Share:-$2.55

Book Value & Capital (2)

Book Value Per Share:$1.75
Cash Per Share:3.33

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.35x
Working Capital Turnover Ttm:0.53x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:6.71
Cash Conversion Cycle:-2,004.71
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:40.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$58.77M

Damodaran Growth Analysis (2)

Reinvestment Rate:2.3%
Fundamental Growth Rate (g):-3.5%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-50.0%

Other Growth Rates (1)

Book Value Growth Rate (Linear):-7.4%
C. Company Profile & Context

Corporate Information (6)

Symbol:DTIL
Company Name:PRECISION BIOSCIENCES INC
Sector:Healthcare
Industry:Biological Products, (No Diagnostic Substances)
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:25.86M
Shares Outstanding Basic:25.86M
Shares Outstanding Diluted:25.86M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-21 18:11:27 UTC
Data Timestamp:2026-08-19T01:19:36.809297
Scroll to Top